Logo-ipp
Submitted: 06 Aug 2021
Accepted: 22 May 2022
ePublished: 19 Jun 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

  Abstract View: 712

Original

Serum level of interleukin-17 in patients with psoriasis

Mohammadreza Sobhan 1 ORCID logo, Hamid Reza Ghasemi Basir 1,2* ORCID logo, Mohammad Ali Seif Rabiee 3 ORCID logo, Fariba Shadfar 4 ORCID logo

1 Psoriasis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2 Department of Pathology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Community Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4 School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Correspondence to Hamid Reza Ghasemi Basir, Email: ha.ghasemi@umsha. ac.ir, hrgb2004@yahoo.com

Abstract

Introduction: Psoriasis is one of the most common chronic and disabling dermatoses. Recent studies showed that interleukin-17 (IL-17) may play a role in the development of psoriasis.

Objectives: In this study, serum levels of IL-17 in psoriatic patients was compared with healthy controls; besides, in patients with psoriasis, serum levels of IL-17 were compared with pre-treatment levels, after topical treatments.

Patients and Methods: In this case-control study, serum levels of IL-17 were measured and compared in 30 psoriatic patients and 30 healthy individuals matched to age, gender and body mass index. After evaluating the severity of psoriasis with PASI (Psoriasis Area Severity Index), they were treated with psoriasis topical corticosteroids for four weeks. IL-17 and PASI levels were re-evaluated after the treatment without any intervention.

Results: Before the start of treatment, the mean±SD of serum level of IL-17 was 6.24±4.65 pg/mL and 2.0 ± 0.75 pg/mL in psoriatic patients and control group, respectively (P=0.001). The mean±SD of PASI severity scale of patients was 10.68 ± 6.65 and 6.16±4.2 before and after treatment, respectively (P<0.001). The mean±SD of serum level of IL-17 of patients before and one month after treatment were 6.24±4.65 and 3.34±1.77 pg/mL, respectively.

Conclusion: In psoriatic patients, serum levels of IL-17 increased significantly compared to healthy subjects. Treatment of psoriasis with topical corticosteroids for four weeks reduced the serum level of IL-17 and the severity of disease.

Keywords: Psoriasis, Interleukin 17
Citation: Sobhan M, Ghasemi Basir HR, Seif Rabiee MA, Shadfar F. Serum level of interleukin-17 in patients with psoriasis. Immunopathol Persa. 2022;x(x):e29269. DOI:10.34172/ ipp.2022.29269.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 713

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.